Designing prospective clinical pharmacogenomic (PG) trials: Meeting report on drug development strategies to enhance therapeutic decision making

Pharmacogenomics Journal

Volumn 6, Issue 2, 2006, Pages 89-94

  Trepicchio, W L ^a   Essayan, D ^b   Hall, S T ^c   Schechter, G ^d   Tezak, Z ^e   Wang, S J ^f   Weinreich, D ^g   Simon, R ^h  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b AMGEN INC   (United States)

^c GLAXOSMITHKLINE   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g Gene Logic   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETERMAN; BEVACIZUMAB; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; CURESIT; DIA 0001; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IRINOTECAN; MESSENGER RNA; MONOCLONAL ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACCURACY; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DNA MICROARRAY; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DESIGN; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; PATIENT IDENTIFICATION; PHARMACOGENOMICS; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; CLINICAL TRIALS; DECISION MAKING; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACOGENETICS; PROSPECTIVE STUDIES; RESEARCH DESIGN;

EID: 33645070310     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500344     Document Type: Conference Paper

References (12)

1. Eiermann W. Trastuzumab combined with chemotherapy for the treatment of HER2 positive metastatic breast cancer: Pivotal trial data. Ann Oncol 2001; 12(Suppl 1): S57-S62.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Branigan BW. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 2004; 350: 2129-2139.
3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
4. Spear BS, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7: 201-204.
5. http://www.fda.gov/cder/guidance/5900dft.pdf.
6. Salerno RA, Lesko LJ. Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 2004; 5: 503-505.
7. Trepicchio WL, Williams GA, Essayan D, Hall ST, Harty LC, Shaw PM et al. Pharmacogenomic data submissions to the FDA: Clinical case studies. Pharmacogenomics 2004; 5: 519-524.
8. Roses AD. Pharmacogenetics and drug development: The path to safer and more effective drugs. Nat Rev 2004; 5: 645-656.
9. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the analysis of DNA microarray data: Class prediction methods. J Natl Cancer Inst 2003; 95: 14-18.
10. Simon R. Diagnostic and prognostic prediction using gene expression profiles in high dimensional microarray data. Br J Cancer 2003; 89: 1599-1604.
11. Simon R, Maitnourim A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004; 10: 6759-6763.
12. Freidlin B, Simon R. Adaptive signature design. An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005; 11: 7872-7878.